Stéphane Auvin

Jul 23, 2024 | onlinelibrary.wiley.com | Ann-Sofie De Meulemeester |Institut du Cerveau |Christopher Reid |Stéphane Auvin

CONFLICT OF INTEREST STATEMENT SA is deputy editor for Epilepsia. He has served as a consultant or received honoraria for lectures from Angelini Pharma, Biocodex, BioMarin, Encoded, Eisai, GRIN Therapeutics, Jazz Pharmaceutics, Neuraxpharm, Nutricia, Orion, UCB Pharma, Xenon, and Zogenix. He has been an investigator for clinical trials for Eisai, Marinus, Proveca, UCB Pharma, Xenon and Zogenix. S.L.M. was associate editor of Neurobiology of Disease until December 2021.

Jun 22, 2024 | onlinelibrary.wiley.com | Jo Sourbron |Stéphane Auvin |Leonor Isip Cabral-Lim |A Php

CONFLICT OF INTEREST STATEMENT We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Feb 14, 2024 | onlinelibrary.wiley.com | Stéphane Auvin |CRMR épilepsies rares |Yann De Rycke |Sylvie Guillo

CONFLICT OF INTEREST STATEMENT S.A. has served as a consultant for or received honoraria for lectures from Angelini Pharma, Biocodex, BioMarin, Eisai, GW Pharma, Neuraxpharm, Nutricia, UCB Pharma, Xenon, and Zogenix. He has been an investigator for clinical trials for Eisai, UCB Pharma, Xenon, and Zogenix.

Sep 7, 2023 | onlinelibrary.wiley.com | Stéphane Auvin |Aristea S Galanopoulou |Solomon L Moshé |EpiCare ERN Member

CONFLICT OF INTEREST STATEMENT S. Auvin is Deputy Editor for Epilepsia. He has served as consultant or given lectures for Angelini, Biocodex, Eisai, Encoded, Grintherapeutics, Jazz Pharmaceuticals, Neuraxpharm, Orion, Nutricia, Proveca, UCB Pharma, Vitaflo, Xenon, and Zogenix. He has been investigator for clinical trials for Eisai, Jazz Pharmaceuticals, Marinus, Proveca, Takeda, UCB Pharma, and Zogenix.